Abstract
Abstract
Various 5-substituted-2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)hydrazinecarbothioamide (4a, b) and 5-substituted-2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-(phenyl-4-substituted)hydrazinecarbothioamide (5a–h) derivatives were synthesized. The compounds were screened for cytotoxicity against human HeLa and CEM T-lymphocytes as well as murine L1210 cells. The compounds were also screened for β-lactamase inhibitory activity, antiviral, antibacterial, and antifungal activity against various strains of microorganisms. Several of these compounds were endowed with low micromolar 50 %-cytostatic concentration (IC50) values, and some were virtually equally potent as melphalan. The most potent inhibitors against the murine leukemia cells (L1210) were also the most inhibitory against human T-lymphocyte (CEM) tumor cells. Derivative 2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazinecarbothioamide 5c emerged as the most potent cytostatic compound among the tested compounds. Derivatives 4b, 5a, 5b, and 5d showed antiviral activity against HEL cell cultures (IC50 11–20 μM). Moderate antimicrobial activity was observed for all derivatives. The encouraging cytostatic and antiviral activity data provide an adequate rationale for further modification of these molecular scaffolds.
Graphical abstract
Derivative 5c (1.9–4.4 μM) emerged as the most potent cytostatic compound among the tested compounds. Derivatives 4b, 5a, 5b, and 5d showed antiviral activity against HEL cell cultures (IC50 11–20 μM). 
Keywords: 2,3-Dioxo-2,3-dihydroindole; Thiosemicarbazones; Cytotoxicity assay; Antiviral activity; Antimicrobial activity
Introduction
Isatin has been known for about 150 years and has recently been found, like 2,3-dioxo-indoles and endogenous polyfunctional heterocyclic compounds, to exhibit biological activity in mammals (Somogyi, 2001). Schiff bases and Mannich bases of isatin are known to possess a wide range of pharmacological properties including antibacterial (Pandeya et al., 1998; Sarangapani and Reddy, 1994; Varma and Nobles, 1975), anticonvulsant (Sridhar et al., 2002; Varma et al., 2004), anti-HIV (Pandeya et al., 1998, 1999a, b, 2000; Sriram et al., 2000), antifungal (Pandeya et al., 1999a, b), antiviral (Singh et al., 1983), and anticancer activity (Fig. 1) (Karki et al., 2004, 2007, 2009). A variety of 3-substituted indolin-2-ones have been utilized as anticancer drugs or drug candidates (Mologni et al., 2010, Beauchard et al., 2009, Zhang and Go 2009, Andreani et al., 2010). A representative member of this class is sunitinib [SU11248, Sutent™; Pfizer, Inc.] which is currently used in the clinics as a multi-targeting tyrosine kinase inhibitor with antiangiogenic activity (Fig. 1) (Sun et al., 2003). 6-Methoxycarbonyl group-substituted indolin-2-ones [BIBF1000, BIBF1120] are potent inhibitors of VEGFR-1/2/3, PDGFRa, and FGFR-1, with low cross-reactivity against a panel of other kinases (Fig. 1) (Roth et al., 2009). While BIBF1120 is currently being evaluated in phase III clinical trials in the treatment of non-small cell lung cancer and is in clinical development for other tumor types. Indirubin was identified as the active ingredient of a traditional Chinese recipe [Danggui Longhui Wan] that was used for the treatment of chronic myelogenous leukemia (CML) (Fig. 1) (Xiao et al., 2002).
Fig. 1.
Structures of indolin-2-ones
Thiosemicarbazones of various aldehydes and ketones occupy a special place among organic ligands, since they contain various donor atoms and are able to change density depending on the starting reagents and their reaction conditions. Isatin-3-thiosemicarbazones (1H-indole-2,3-dioxo-3-thiosemicarbazones) have been studied extensively due to their important biological activities (Karki et al., 2009), since 1-methylisatin-3-thiosemicarbazone (Marboran) was found to be active in the treatment of smallpox. Previous studies by our group have revealed the promising cytotoxic, and anticonvulsant properties of various 2,3-dioxo-2,3-dihydroindole thiosemicarbazones (Fig. 1) (Karki et al., 2009). Therefore, we have performed the synthesis of new N-4-aryl thiosemicarbazone derivatives of substituted 2,3-dioxo-2,3-dihydroindoles and evaluated them for cytotoxic, antiviral, and antimicrobial activity.
Results and discussion
Chemistry
The compounds in series 4 and 5 were prepared by the methodologies outlined in Scheme 1. The synthesis of 1-[(diethylamino)methyl]-1H-indole-2,3-dione derivatives (3) was carried out by mannich base reaction of 2,3-dioxy-2,3-dihydroindoles or 5-chloro-2,3-dioxy-2,3-dihydroindoles (2) with diethylamine in the presence of formaldehyde. The synthesis of N-diethylaminomethyl-2-oxo-1,2-dihydroindole hydrazinecarbothioamides (4a, b, 5a–h) was carried out by reacting 1-[(diethylamino)methyl]-1H-indole-2,3-dione derivatives (3) with thiosemicarbazide and N 4-aryl thiosemicarbazides under reflux in ethanol in the presence of catalytic amounts of glacial acetic acid. 1H-NMR spectroscopy indicated that the compounds exist as single isomers in solution.
Scheme 1.
The reagents used were as follows: i CCl3CH(OH)2/H2SO4/Na2SO4; R 1=H, Cl, ii (C2H5)NH/HCHO, iii NH2C(S)NHNH2, iv R 2C6H4NHC(S)NHNH2. The nature of the R 1 and R 2 substituent are presented in Table 1
Biological activity
All of the compounds were assayed for cytotoxicity against human HeLa and CEM T-lymphocytes as well as murine L1210 cells. These data are summarized in Table 1. Compound 5c was the most cytostatic among all compounds evaluated against the tumor cell lines (IC50 in the low micromolar range (1.9–4.4 μM)).
Table 1.
Results of cytotoxicity in murine L1210 cells, human HeLa, and CEM T-lymphocytes, and β-lactamase inhibitory activity
| Compound | R 1 | R 2 | IC50 a (μM) | Time for decolorization of I2 (s) | Activity (u ml−1) | Inactivation (%) | ||
|---|---|---|---|---|---|---|---|---|
| L1210 | CEM | HeLa | ||||||
| 4a | H | – | 121 ± 35 | 164 ± 21 | 123 ± 85 | 128.6 | 46.7 | 38.2 |
| 4b | Cl | – | 148 ± 15 | 71 ± 7 | 44 ± 22 | 121.5 | 49.4 | 34.6 |
| 5a | H | H | 13 ± 3 | 11 ± 0 | 8.3 ± 0.0 | 159.5 | 37.6 | 50.2 |
| 5b | H | Cl | 11 ± 1 | 10 ± 1 | 7.6 ± 0.9 | 129.7 | 46.3 | 38.7 |
| 5c | H | OCH3 | 2.4 ± 0.0 | 1.9 ± 0.9 | 4.4 ± 2.4 | 123.6 | 48.5 | 35.7 |
| 5d | H | CH3 | 29 ± 3 | 12 ± 0 | 12 ± 0 | 145.8 | 41.2 | 45.5 |
| 5e | Cl | H | 49 ± 2 | 40 ± 3 | 34 ± 0 | 156.3 | 38.4 | 49.2 |
| 5f | Cl | Cl | >125 | >125 | >125 | 142.3 | 42.2 | 44.2 |
| 5g | Cl | OCH3 | 11 ± 2 | 6.9 ± 4.3 | 9.2 ± 0.9 | 167.9 | 35.7 | 52.6 |
| 5h | Cl | CH3 | 9.5 ± 0.5 | 4.6 ± 4.0 | 8.6 ± 0.3 | 120.6 | 49.8 | 34.1 |
| Melphalan | – | – | 3.2 ± 0.6 | 2.2 ± 0.2 | 2.1 ± 0.02 | – | – | – |
| Control | – | – | – | – | – | 79.5 | 75.5 | – |
| Potassium clavulanate | – | – | – | – | – | 240.50 | 25.0 | 67.0 |
aIC50 concentrations of compounds required to inhibit the growth of the tumor cells by 50 %
The most potent inhibitor of murine L1210 cell proliferation (5c) was also the most inhibitory to human T-lymphocyte (CEM) and HeLa cell proliferation. The introduction of R 2-benzyl substitution in the thiosemicarbazone derivative of series 5 often led to more potent inhibitors of tumor cell proliferation (5a–h). Replacement of the hydrogen by chlorine atom did not improve the potentiation of the cytostatic activity (compare 5a with 5b) (Table 1). Whereas, replacement of the chlorine atom at R 2 by a methoxy group often resulted in a marked (equal) potentiation of cytostatic activity (5b with 5c).
Replacement of hydrogen atom at R 1 by chlorine atom did not yield any improvement in potency (compare 5a, 5b and 5d with 5e–h). Replacing hydrogen atom at R 1 and R 2 by chlorine resulted in a complete loss of activity (5f). By keeping chlorine atom at R 1 and CH3 and OCH3 at R 2, resulted in slight improvement of cytostatic activity (5g and 5h).
The antiviral screening of 4a, b and 5a–h was performed using an MTS-based CPE reduction assay (Kumar et al., 2010) against feline corona virus (FIPV) and feline herpes virus in CRFK cell culture; herpes simplex virus-1 (KOS) (HSV-1 KOS), herpes simplex virus-2 (G) (HSV-2G), vaccinia virus (VV), vesicular stomatitis virus (VSV), and herpes simplex virus-1 TK KOS ACVr (HSV-1 TK KOS ACVr) in HEL cell cultures; VSV, Coxsackie virus B4 (CV-B4), and respiratory syncytial virus (RSV) in HeLa cell cultures; influenza A virus H1N1 subtype, influenza A virus H3N2 subtype, and influenza B virus in MDCK cell cultures; parainfluenza-3 virus (PI-3V), reovirus-1 (RV-1), Sindbis virus (SV), CV-B4, and Punta Toro virus (PTV) in Vero cell cultures.
Compounds 4b, 5a, 5b, and 5d exhibited moderate antiviral activity in HEL cells in comparison to standard compounds. No specific antiviral effects were noted for any of the compounds in CRFK, MDCK, or Vero cell cultures (Tables 2, 3, 4, 5, 6).
Table 2.
Results of anti-FIPV and anti-feline herpes virus activity and cytotoxicity in CRFK cell cultures
| Compound | CC50 a (μM) | EC50 b (μM) | |
|---|---|---|---|
| FIPV | Feline herpes virus | ||
| 4a | 73.8 | >20 | >20 |
| 4b | >100 | >100 | >100 |
| 5a | 32.3 | >20 | >20 |
| 5b | 4.0 | >0.8 | >0.8 |
| 5c | 3.5 | >0.8 | >0.8 |
| 5d | 3.8 | >0.8 | >0.8 |
| 5e | 6.9 | >4 | >4 |
| 5f | 9.1 | >4 | >4 |
| 5g | 3.6 | >0.8 | >0.8 |
| 5h | 17.5 | >4 | >4 |
| HHA (μg ml−1) | >100 | 19.5 | 1.8 |
| UDA (μg ml−1) | >100 | 9.1 | 2.4 |
| Ganciclovir | >100 | >100 | 7.3 |
a50 % cytotoxic concentration
b50 % effective concentration, determined by colorimetric formazan-based MTS assay
Table 3.
Results of cytotoxicity and antiviral activity of compounds in HEL cell cultures
| Compound | Minimum cytotoxic concentrationa (μM) | EC50 b (μM) | ||||
|---|---|---|---|---|---|---|
| HSV-1 (KOS) | HSV-2 (G) | VV | VSV | HSV-1 TK− KOS ACVr | ||
| 4a | >100 | >100 | >100 | >100 | >100 | >100 |
| 4b | >100 | >100 | >100 | 20 | >100 | >100 |
| 5a | >100 | 20 | 15 | 20 | >100 | >100 |
| 5b | 100 | 15 | 15 | ≥20 | >20 | ≥20 |
| 5c | 100 | >20 | >20 | >20 | >20 | >20 |
| 5d | 100 | 14 | 12 | 11 | >20 | ≥20 |
| 5e | 100 | >20 | >20 | >20 | >20 | >20 |
| 5f | 100 | >20 | >20 | >20 | >20 | >20 |
| 5g | 100 | >20 | >20 | >20 | >20 | >20 |
| 5h | 100 | >20 | >20 | >20 | >20 | >20 |
| Brivudin | >250 | 0.08 | 150 | 29 | >250 | >250 |
| Cidofovir | >250 | 5 | 1.5 | 10 | >250 | 6 |
| Acyclovir | >250 | 1.0 | 0.7 | >250 | >250 | >250 |
| Ganciclovir | >100 | 0.09 | 0.07 | >100 | >100 | ≥20 |
aRequired to cause a microscopically detectable alteration of normal cell morphology
bRequired to reduce virus-induced cytopathogenicity by 50 %
Table 4.
Results of cytotoxicity and antiviral activity of compounds in HeLa cell cultures
| Compound | Cytotoxicity (μM) | EC50 b (μM) | ||||||
|---|---|---|---|---|---|---|---|---|
| CC50 a | Minimum cytotoxic concentrationb | VSV | CV-B4 | RSV | ||||
| Visual CPE score | MTS | Visual CPE score | MTS | Visual CPE score | MTS | |||
| 4a | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 4b | >100 | >100 | >100 | >100 | >100 | >100 | >100 | >100 |
| 5a | 10.8 | ≥20 | >20 | >20 | >20 | >20 | >20 | >20 |
| 5b | 9.8 | ≥4 | >4 | >4 | >4 | >4 | >4 | >4 |
| 5c | >100 | ≥4 | >4 | >4 | >4 | >4 | >4 | >4 |
| 5d | 10.7 | ≥20 | >20 | >20 | >20 | >20 | >20 | >20 |
| 5e | 13.5 | ≥20 | >20 | >20 | >20 | >20 | >20 | >20 |
| 5f | 9.4 | 100 | >20 | >20 | >20 | >20 | >20 | >20 |
| 5g | 13.2 | 4 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 |
| 5h | >100 | ≥4 | >4 | >4 | >4 | >4 | >4 | >4 |
| DS-5000c | >100 | >100 | 20 | 14.8 | >100 | >100 | 4 | 2.8 |
| (S)-DHPA | >250 | >250 | >250 | >250 | >250 | >250 | >250 | >250 |
| Ribavirin | >250 | >250 | 50 | 12.1 | 50 | 28.5 | 10 | 4.6 |
a50 % cytotoxic concentration
bMinimum compound concentration that causes a microscopically detectable alteration of normal cell morphology
c50 % effective concentration, as determined by a colorimetric formazan-based MTS assay. Data in μg ml−1
Table 5.
Results of cytotoxicity and antiviral activity of compounds in Vero cell cultures
| Compound | Minimum cytotoxic concentrationa (μM) | EC50 b (μM) | ||||
|---|---|---|---|---|---|---|
| PI-3V | RV-1 | SV | CV-B4 | PTV | ||
| 4a | >100 | >100 | >100 | >100 | >100 | >100 |
| 4b | >100 | >100 | >100 | >100 | >100 | >100 |
| 5a | 100 | >20 | >20 | >20 | >20 | >20 |
| 5b | 20 | >4 | >4 | >4 | >4 | >4 |
| 5c | 4 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 |
| 5d | 100 | >20 | >20 | >20 | >20 | >20 |
| 5e | 100 | >20 | >20 | >20 | >20 | >20 |
| 5f | 100 | >20 | >20 | >20 | >20 | >20 |
| 5g | 4 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 |
| 5h | ≥4 | >4 | >4 | >4 | >4 | >4 |
| DS-5000c | >100 | >100 | >100 | 20 | 100 | 100 |
| (S)-DHPA | >250 | 250 | 250 | >250 | >250 | >250 |
| Ribavirin | >250 | 50 | >250 | >250 | >250 | 112 |
aRequired to cause a microscopically detectable alteration of normal cell morphology
bRequired to reduce virus-induced cytopathogenicity by 50 %
cData in μg ml−1
Table 6.
Results of anti-influenza virus activity and cytotoxicity in MDCK cell cultures
| Compound | Cytotoxicity (μM) | Antiviral EC50 c (μM) | ||||||
|---|---|---|---|---|---|---|---|---|
| CC50 a | Minimum cytotoxic concentrationb | Influenza A H1N1 subtype |
Influenza A H3N2 subtype |
Influenza B | ||||
| Visual CPE score | MTS | Visual CPE score | MTS | Visual CPE score | MTS | |||
| 4a | 85.8 | 100 | >20 | >20 | >20 | >20 | >20 | >20 |
| 4b | 78.3 | 100 | >20 | >20 | >20 | >20 | >20 | >20 |
| 5a | 1.6 | 0.8 | >0.16 | >0.16 | >0.16 | >0.16 | >0.16 | >0.16 |
| 5b | 0.4 | 0.8 | >0.16 | >0.16 | >0.16 | >0.16 | >0.16 | >0.16 |
| 5c | 9.2 | 4 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 |
| 5d | 0.2 | 0.8 | >0.16 | >0.16 | >0.16 | >0.16 | >0.16 | >0.16 |
| 5e | 3.0 | ≥0.8 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 |
| 5f | 2.4 | ≥0.8 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 |
| 5g | 11.1 | ≥0.8 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 |
| 5h | 11.3 | 4 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 | >0.8 |
| Oseltamivir carboxylate | >100 | >100 | 45 | 39.1 | 4 | 5.7 | 45 | 21.8 |
| Ribavirin | >100 | ≥100 | 9 | 11.5 | 9 | 6.8 | 9 | 8.4 |
| Amantadine | >500 | >500 | 45 | 65.5 | 2 | 1.5 | >500 | >500 |
| Rimantadine | 258.9 | 500 | 9 | 24.2 | 0.1 | 0.08 | >100 | >100 |
a50 % cytotoxic concentration, as determined by colorimetric formazan-based MTS assay
bMinimum compound concentration that causes a microscopically detectable alteration of normal cell morphology
c50 % effective concentration, as determined by colorimetric formazan-based MTS assay
All the synthesized compounds were screened for β-lactamase inhibitory activity and results are shown in Table 1. Compounds namely 5a and 5g were capable of inactivating β-lactamase activity, and for other compounds activity was moderate in comparing to standard potassium clavulanate. Titled compounds were also screened for antibacterial activity against S. aureus, B. subtilis, K. pneumoniae, E. coli, P. vulgaris, and S. typhi and antifungal activity against A. niger and C. albicans and exhibited moderate antimicrobial activity (Table 7).
Table 7.
Zone of Inhibition in mm (using 50 μg ml−1 as test solution)
| Compound | Antibacterial activity | Antifungal activity | ||||||
|---|---|---|---|---|---|---|---|---|
| S. aureus | B. subtilis | K. pneumoniae | E. coli | P. vulgaris | S. typhi | A. niger | C. albicans | |
| 4a | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| 4b | +++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ |
| 5a | ++ | ++ | ++ | ++ | +++ | +++ | +++ | +++ |
| 5b | ++ | +++ | ++ | +++ | ++ | ++ | ++ | ++ |
| 5c | ++ | ++ | ++ | ++ | +++ | +++ | ++ | ++ |
| 5d | +++ | +++ | ++ | +++ | ++ | +++ | ++ | ++ |
| 5e | ++ | ++ | ++ | ++ | +++ | ++ | ++ | +++ |
| 5f | +++ | +++ | ++ | +++ | +++ | +++ | +++ | +++ |
| 5g | ++ | ++ | ++ | ++ | +++ | +++ | ++ | ++ |
| 5h | ++ | ++ | ++ | +++ | ++ | ++ | ++ | ++ |
| Ofloxacin | ++++ | ++++ | ++++ | ++++ | ++++ | ++++ | – | – |
| Fluconazole | – | – | – | – | – | – | ++++ | ++++ |
| Control | + | + | + | + | + | + | + | + |
++++ (31–36), +++ (21–30), ++ (11–20), + (8–10) in mm
Experimental
Chemistry
All reagents were obtained from Sigma-Aldrich, Mumbai, and Loba Chemie, Mumbai. All the solvents used in these studies were dried and distilled before use. Melting points (Mp): Veego VMP-PM digital melting point apparatus, and are uncorrected. TLC: solvent benzene:ethanol (8:2). UV spectra: Shimadzu Pharmspec 1700, UV–Vis spectrophotometer. IR spectra: Shimadzu 8400 S, FT-IR. 1H-NMR spectra: 300 MHz JEOL NMR Spectrophotometer in CDCl3 and DMSO-d6. Mass spectra: GCMS QP 5050 Shimadzu. All spectra were obtained from Pune University, Maharashtra, India.
Syntheses of the intermediate 2,3-dioxy-2,3-dihydroindoles
The synthesis of the intermediate 2,3-dioxo-2,3-dihydroindoles was accomplished using a literature methodology (Marvel and Heirs, 1941) and a previously reported procedure was used to convert these compounds to the corresponding 1-[(diethylamino)methyl]-1H-indole-2,3-dione. The N 4-arylthiosemicarbazides required for the preparation of 4a, b and 5a–h was prepared by a literature methodology (Sen and Sengupta, 1962; Lieber et al., 1957).
General procedure for syntheses of 4a, b
A mixture of the 1-[(diethylamino)methyl]-1H-indole-2,3-dione or 5-chloro-1-[(diethylamino)methyl]-1H-indole-2,3-dione (0.005 mol), thiosemicarbazides (0.005 mol), acetic acid (0.5–1.0 ml), and ethanol (100 ml) was heated under reflux until the reaction was completed (~4 h). Approximately half of the ethanol was removed in vacuo and the solution was left overnight at room temperature. The precipitated solid was collected, washed with cold ethanol, and recrystallized from ethanol:chloroform (9:1) to give the following compounds.
2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)hydrazinecarbothioamide (4a)
% Yield: 83, m.p.: 134–136 °C; IR (KBr) (cm−1): 1131 (C=S), 1307 (C–N), 1696 (C=O), 3005 (C–H), 3143 (NH), 3238, 3256 (NH2); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.4 (q, 4H, 2CH2), 4.03 (s, 2H, N–CH2), 7.0–7.7 (m, 4H, Ar–H), 9.53 (s, 2H, NH2), 11.18 (s, 1H, NH); calc. for C14H19N5OS: C-55.06, H-6.27 and N-22.93, found C-55.18, H-6.15 and N-22.69.
2-(5-chloro-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)hydrazinecarbothioamide (4b)
% Yield: 64, m.p.: 214–216 °C; IR (KBr) (cm−1): 1127 (C=S), 1305 (C–N), 1698 (C=O), 3008 (C–H), 3136 (NH), 3227, 3246 (NH2); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.4 (q, 4H, 2CH2), 4.03 (s, 2H, N–CH2), 7.0–7.7 (m, 3H, Ar–H), 9.53 (s, 2H, NH2), 11.18 (s, 1H, NH); calc. for C14H18ClN5OS: C-49.48, H-5.34 and N-20.61, found C-49.34, H-5.21 and N-20.69.
General procedure for syntheses of 5a–h
A mixture of the 1-[(diethylamino)methyl]-1H-indole-2,3-dione or 5-chloro-1-[(diethylamino)methyl]-1H-indole-2,3-dione (0.005 mol), N 4-aryl thiosemicarbazides (0.005 mol), acetic acid (0.5–1.0 ml), and ethanol (100 ml) was heated under reflux until the reaction was completed (approximately 4 h). Approximately half of the ethanol was removed in vacuo and the solution was left overnight at room temperature. The precipitated solid was collected, washed with cold ethanol, and recrystallized from ethanol:chloroform (9:1) to give the following compounds.
2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-phenylhydrazinecarbothioamide (5a)
% Yield: 69, m.p.: 230–232 °C; IR (KBr) (cm−1): 1127 (C=S), 1304 (C–N), 1713 (C=O), 3008 (C–H), 3143, 3217 (NH); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.4 (q, 4H, 2CH2), 4.03 (s, 2H, N–CH2), 6.9–7.7 (m, 9H, Ar–H), 11.29 (s, 1H, N–NH), 11.52 (s, 1H, NH); calc. for C20H23N5OS: C-62.97, H-6.08 and N-18.36, found C-62.53, H-5.87 and N-18.15.
N-(4-chlorophenyl)-2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)hydrazine carbothioamide (5b)
% Yield: 74, m.p.: 151–153 °C; IR (KBr) (cm−1): 1129 (C=S), 1317 (C–N), 1716 (C=O), 3006 (C–H), 3128, 3209 (NH); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.4 (q, 4H, 2CH2), 4.03 (s, 2H, N–CH2), 6.4–7.7 (m, 8H, Ar–H), 11.29 (s, 1H, N–NH), 11.52 (s, 1H, NH); calc. for C20H22ClN5OS: C-57.75, H-5.33 and N-16.84, found C-57.39, H-5.26 and N-16.53.
2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazinecarbothioamide (5c)
% Yield: 77, m.p.: 177–179 °C; IR (KBr) (cm−1): 1119 (C=S), 1325 (C–N), 1706 (C=O), 3008 (C–H), 3120, 3202 (NH); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.4 (q, 4H, 2CH2), 3.75 (s, 3H, O–CH3), 4.03 (s, 2H, N–CH2), 6.3–7.7 (m, 8H, Ar–H), 11.29 (s, 1H, N–NH), 11.52 (s, 1H, NH); calc. for C21H25N5O2S: C-61.29, H-6.12 and N-17.02, found C-61.09, H-6.09 and N-16.80.
2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-p-tolylhydrazinecarbothioamide (5d)
% Yield: 67, m.p.: 191–193 °C; IR (KBr) (cm−1): 1125 (C=S), 1297 (C–N), 1706 (C=O), 3008 (C–H), 3135, 3219 (NH); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.32 (s, 3H, CH3), 2.4 (q, 4H, 2CH2), 4.03 (s, 2H, N–CH2), 6.3–7.7 (m, 9H, Ar–H), 11.29 (s, 1H, N–NH), 11.52 (s, 1H, NH); calc. for C21H25N5OS: C-63.77, H-6.37 and N-17.71, found C-63.42, H-6.14 and N-17.39.
2-(5-chloro-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-phenylhydrazinecarbothioamide (5e)
% Yield: 72, m.p.: 181–183 °C; IR (KBr) (cm−1): 1125 (C=S), 1315 (C–N), 1718 (C=O), 3008 (C–H), 3123, 3219 (NH); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.4 (q, 4H, 2CH2), 4.03 (s, 2H, N–CH2), 6.9–7.7 (m, 8H, Ar–H), 11.29 (s, 1H, N–NH), 11.52 (s, 1H, NH); calc. for C20H22ClN5OS: C-57.75, H-5.33 and N-16.84, found C-57.51, H-5.37 and N-16.27.
2-(5-chloro-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-(4-chlorophenyl)hydrazinecarbothioamide (5f)
% Yield: 79, m.p.: 219–221 °C; IR (KBr) (cm−1): 1114 (C=S), 1310 (C–N), 1713 (C=O), 3007 (C–H), 3123, 3216 (NH); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.4 (q, 4H, 2CH2), 4.03 (s, 2H, N–CH2), 6.4–7.6 (m, 8H, Ar–H), 11.29 (s, 1H, N–NH), 11.52 (s, 1H, NH); calc. for C20H21Cl2N5OS: C-53.34, H-4.70 and N-15.55, found C-53.29, H-4.54 and N-15.28.
2-(5-chloro-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazinecarbothioamide (5g)
% Yield: 73, m.p.: 165–167 °C; IR (KBr) (cm−1): 1123 (C=S), 1329 (C–N), 1716 (C=O), 3008 (C–H), 3127, 3224 (NH); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.4 (q, 4H, 2CH2), 3.75 (s, 3H, O–CH3), 4.03 (s, 2H, N–CH2), 6.3–7.7 (m, 7H, Ar–H), 11.29 (s, 1H, N–NH), 11.52 (s, 1H, NH); calc. for C21H24ClN5O2S: C-56.56, H-5.42 and N-15.70, found C-56.26, H-5.32 and N-15.47.
2-(5-chloro-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-p-tolylhydrazinecarbothioamide (5h)
% Yield: 72, m.p.: 178–180 °C; IR (KBr) (cm−1): 1128 (C=S), 1309 (C–N), 1711 (C=O), 3008 (C–H), 3125, 3228 (NH); 1H-NMR (CDCl3) δ (ppm): 1.0 (t, 6H, 2CH3), 2.32 (s, 3H, CH3), 2.4 (q, 4H, 2CH2), 4.03 (s, 2H, N–CH2), 6.3–7.7 (m, 8H, Ar–H), 11.29 (s, 1H, N–NH), 11.52 (s, 1H, NH); calc. for C21H24ClN5OS: C-58.66, H-5.63 and N-16.29, found C-58.43, H-5.38 and N-16.31.
Cytotoxicity assays
The methodology for undertaking the HeLa, CEM, and L1210 assays has been published previously (Baraldi et al., 2004). In brief, varying concentrations of the compounds were incubated at 37 °C for 72 h (HeLa and CEM T-lymphocytes) or 48 h (L1210 cells) in 200-μl 96-well-microtiter plates, and the viable tumor cell number was counted at the end of the incubation period using a Coulter Counter (Coulter Electronics, Harpenden Hertz, U.K.).
Antiviral assay
The antiviral screening of 4a, b and 5a–h was performed against FIPV and feline herpes virus in CRFK cell culture; HSV-1 KOS, HSV-2G, VV, VSV, and HSV-1 TK KOS ACVr in HEL cell cultures; VSV, CVB4, and RSV in HeLa cell cultures; PI-3V, RV-1, SV, CV-B4, and PTV in Vero cell cultures; influenza A virus H1N1 subtype, influenza A virus H3N2 subtype, and influenza B virus in MDCK cell cultures and the results are expressed as the 50 % effective concentration (EC50). Cells, grown to confluency in 96-well plates, were infected with 100 CCID50 of virus, one CCID50 being the 50 % cell culture infective dose. At the time of virus infection, serial dilutions of the compounds were added. The cultures were incubated at 37 °C for 3 days, until complete CPE was observed in the infected and untreated virus control.
Cytotoxicity assay
The cytotoxicity of the compounds was evaluated in parallel with their antiviral activity in uninfected cells, and is expressed as the minimum cytotoxic concentration to cause a microscopically detectable alteration of normal cell morphology (HEL, HeLa, CRFK, MDCK, and Vero cells).
Antiproliferative assays
The cytostatic effects of the test compounds on murine leukemia cells (L1210), human T-lymphocyte cells (CEM), and human cervix carcinoma cells (HeLa) were evaluated as follows: an appropriate number of cells suspended in growth medium were allowed to proliferate in 200-μl wells of 96-well-microtiter plates in the presence of variable amounts of test compounds at 37 °C in a humidified CO2-controlled atmosphere. After 48 h (L1210), 72 h (CEM), or 96 h (HeLa), the number of cells was counted in a Coulter counter. The IC50 value was defined as the compound concentration required to inhibit cell proliferation by 50 %.
β-lactamase inhibitory assay
All reagents were equilibrated to 30 °C in a water bath before adding them to the reaction tubes (20 × 150 mm. Pyrex test tubes) in the following order: first, 1 ml of gelatin solution (1 % in 0.1 M phosphate buffer, pH 7.0), 50 μl of enzyme, one drop of starch solution (1 % soluble starch), 1 ml of Penicillin solution (Crystalline Sodium Penicillin G (Benzyl penicillin) IP, Alembic Ltd.) 1,660 μg mg−1, dissolved in 0.1 M phosphate buffer, pH 7.0, to contain not less than 5,000 μg ml−1), 3 ml of sample solution and finally, 2 ml of iodine (0.01 N iodine in 0.1 M potassium iodide) was added. Then the time of decolorization of iodine was recorded with a stopwatch; after addition of substrate (synthesized compounds), standard (Potassium Clavulanate) and blank was determined using water in place of sample solution.
Unit
Penicillinase activity is expressed in Pollock and Torriani unit. One unit is the amount of enzyme which will hydrolyze 1 μM Sodium Penicillin G in 1 h at pH 7.0 at 30 °C.
Antimicrobial screening
The antimicrobial assays were performed for synthesized compounds by cup-plate method of all the synthesized compounds, as antibacterial activity against S. aureus, B. subtilis, K. pneumoniae, E. coli, P. vulgaris, and S. typhi and antifungal activity against A. niger and C. albicans. This activity was expressed in terms of diameters of zone of inhibition in mm.
Conclusion
In summary, a series of indolin-2-ones with N-diethyl amino and various thiosemicarbazide moiety were designed and synthesized. The cytotoxicity of all synthesized compounds was evaluated against two human cancer cell lines (CEM and HeLa) and murine leukemia cell line (L1210). Compound 5c displayed an excellent cytotoxicity against all three cell lines tested; in particular, it showed potent cytotoxicity against CEM and L1210 cancer cell lines. The preliminary structure–activity relationship (SAR) studies revealed that combination of indolin-2-one core structure and 4-methoxy phenyl thiosemicarbazide moiety at the 3-position was more favorable. All the synthesized compounds were screened for cytotoxicity, β-lactamase inhibitory activity, antiviral, antibacterial, and antifungal activity against various strains of microorganisms. Derivative 4b, 5a, 5b, and 5d showed antiviral activity against HEL cell cultures in the range of 11–20 μM, in comparison with IC50 values of 29, 10, >250, and >100 μM for standard brivudin, cidofovir, acyclovir, and ganciclovir, respectively. Mild to moderate antimicrobial activity was observed. The encouraging biological data provide an adequate rationale for further modification of these molecular scaffolds.
References
- Andreani A, Bellini S, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Calonghi N, Cappadone C, Zini M, Stefanelli C, Masotti L, Shoemaker RH. Substituted E-3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. Effect on the cell cycle and apoptosis. J Med Chem. 2010;53:5567–5575. doi: 10.1021/jm1007165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baraldi PB, Nunez MDelC, Tabrizo MA, De Clercq E, Balzarini J, Bermejo J, Estevez F, Romagnoli R. Design, syntheses and biological evaluation of hybrid molecules containing α-methylene-γ-butyrolactones and polypyrrole minor groove binders. J Med Chem. 2004;47:2877–2886. doi: 10.1021/jm031104y. [DOI] [PubMed] [Google Scholar]
- Beauchard A, Laborie H, Rouillard H, Lozach O, Ferandin Y, Gue´vel RL, Guguen-Guillouzo C, Meijer L, Besson T, Thie´ry V. Synthesis and kinase inhibitory activity of novel substituted indigoids. Bioorg Med Chem. 2009;17:6257–6263. doi: 10.1016/j.bmc.2009.07.051. [DOI] [PubMed] [Google Scholar]
- Karki SS, Mazumder UK, Gupta M, Bhattacharya S, Rathinasamy S, Thangavel S. Synthesis, anticancer and antibacterial activity of some novel mononuclear Ru(II) complexes. Chem Pharm Bull. 2004;52:178–185. doi: 10.1248/cpb.52.178. [DOI] [PubMed] [Google Scholar]
- Karki SS, Shrikanth T, Satyanarayana YD, Balzarini J, De Clercq E. Synthesis, anticancer and cytotoxic activities of some mononuclear Ru(II) compounds. Bioorg Med Chem. 2007;15:6632–6641. doi: 10.1016/j.bmc.2007.08.014. [DOI] [PubMed] [Google Scholar]
- Karki SS, Bahaduria VS, Rana V, Kumar S, Prasanna GS, Das U, Balzarini J, De Clercq E, Dimmock JR. 1-Arylmethyl-2,3-dioxo-2,3-dihydroindole thiosemicarbazones as leads for developing cytotoxins and anticonvulsants. J Enzym Inhib Med Chem. 2009;24:537–544. doi: 10.1080/14756360802234885. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kumar D, Judge V, Narang R, Sangwan S, De Clercq E, Balzarini J, Narasimhan B. Benzylidene/2-chlorobenzylidene hydrazides: synthesis, antimicrobial activity, QSAR studies and antiviral evaluation. Eur J Med Chem. 2010;45:2806–2816. doi: 10.1016/j.ejmech.2010.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lieber E, Pillai ECN, Hites RD. Reactions of nitrous acid with 4-substituted thiosemicarbazides. Can J Chem. 1957;35:832–842. doi: 10.1139/v57-116. [DOI] [Google Scholar]
- Marvel CS, Heirs GS. In isatin. In: Blatt AH, editor. Organic syntheses collection. New York: Wiley; 1941. pp. 327–330. [Google Scholar]
- Mologni L, Rostagno R, Brussolo S, Knowles PP, Kjaer S, Murray-Rust J, Rosso E, Zambon A, Scapozza L, McDonald NQ, Lucchini V, Gambacorti-Passerini C. Synthesis, structure–activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010;18:1482–1496. doi: 10.1016/j.bmc.2010.01.011. [DOI] [PubMed] [Google Scholar]
- Pandeya SN, Yogeeswari P, Sriram D, Nath G. Synthesis and antimicrobial activity of N-Mannich bases of 3-[N′-sulphadooximino] isatin and its methyl derivatives. Bull Chim Farm. 1998;137:321–324. [PubMed] [Google Scholar]
- Pandeya SN, Yogeeswari P, Sriram D, De Clercq E, Pannecouque C, Witvrouw M. Synthesis and screening for anti-HIV activity of some N-Mannich bases of isatin derivatives. J Chemother. 1999;45:192–196. doi: 10.1159/000007182. [DOI] [PubMed] [Google Scholar]
- Pandeya SN, Sriram D, Nath G, De Clercq E. Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-one. Pharm Acta Helv. 1999;74:11–17. doi: 10.1016/S0031-6865(99)00010-2. [DOI] [PubMed] [Google Scholar]
- Pandeya SN, Sriram D, Nath G, De Clercq E. Synthesis, antibacterial, antifungal and anti-HIV activities of Norfloxacin Mannich bases. Eur J Med Chem. 2000;35:249–255. doi: 10.1016/S0223-5234(00)00125-2. [DOI] [PubMed] [Google Scholar]
- Roth GJ, Heckel A, Colbatzky F, Handschuh S, Kley J, Lehmann-Lintz T, Lotz R, Tontsch-Grunt U, Walter R, Hilberg F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) J Med Chem. 2009;52:4466–4480. doi: 10.1021/jm900431g. [DOI] [PubMed] [Google Scholar]
- Sarangapani M, Reddy VM. Synthesis and antimicrobial activity of 1-[(N, N-disubstituted amino)methyl]-3-[(2-phenyl-3,4-dihydro-4-oxoquinazoline-3-yl]indole-2-one. Indian J Heterocycl Chem. 1994;3:257–260. [Google Scholar]
- Sen AB, Sengupta SK. Possible antiamoebic agents. Part XIX. Synthesis of 1,3,4-thiadiazolines and di-1,3,4-thiadiazolines. J Indian Chem Soc. 1962;39:628–634. [Google Scholar]
- Singh SP, Shukla SK, Awasthi LP. Synthesis of some 3-(4′-nitrobenzoylhydrazono)-2-indolinones as a potential antiviral agents. Curr Sci. 1983;52:766–769. [Google Scholar]
- Somogyi L. Transformation of isatin 3-acylhydrazones under acetylating conditions: synthesis and structure elucidation of 1,5′-disubstituted 3′-acetylspiro[oxindole-3,2′-[1,3,4]oxadiazolines] Bull Chem Soc Jpn. 2001;74:873–881. doi: 10.1246/bcsj.74.873. [DOI] [Google Scholar]
- Sridhar SK, Pandeya SN, Stables JP, Ramesh A. The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Eur J Med Chem. 2002;16:129–132. [Google Scholar]
- Sriram D, Pandeya SN, Nath G, De Clercq E. Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin and its derivatives with triazole. Arzneimittelforschung. 2000;50:55–59. doi: 10.1055/s-0031-1300164. [DOI] [PubMed] [Google Scholar]
- Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang XY, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46:1116–1119. doi: 10.1021/jm0204183. [DOI] [PubMed] [Google Scholar]
- Varma RS, Nobles WL. Antiviral, antibacterial, and antifungal activities of isatin N-Mannich bases. J Pharm Sci. 1975;64:881–882. doi: 10.1002/jps.2600640539. [DOI] [PubMed] [Google Scholar]
- Varma M, Pandeya SN, Singh KN, Stables JP. Anticonvulsant activity of Schiff bases of isatin derivatives. Acta Pharm. 2004;54:49–56. [PubMed] [Google Scholar]
- Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. J Leuk Lymph. 2002;43:1763–1768. doi: 10.1080/1042819021000006295. [DOI] [PubMed] [Google Scholar]
- Zhang W, Go ML. Functionalized 3-benzylidene-indolin-2-ones: inducers of NAD(P)H-quinone oxidoreductase 1 (NQO1) with antiproliferative activity. Bioorg Med Chem. 2009;17:2077–2090. doi: 10.1016/j.bmc.2008.12.052. [DOI] [PubMed] [Google Scholar]